Leucine-rich Alpha 2 Glycoprotein-1 (LRG1), Human Plasma | P1431

LRG1 binds cytochrome c, an initiator/amplifier of programmed cell death (apoptosis), and by binding cytochrome c, is thought to play a role in cell survival. LRG1 is a biomarker associated with several cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Recent studies have shown it is three-fold more abundant in ovarian cancer serum compared to non-cancer control serum. LRG1 levels are only moderately correlated with CA125 levels. Elevated levels of LRG1 in the cerebral spinal fluid are being studied as markers for the early diagnosis of Parkinson's disease and progressive supranuclear palsy. In normal plasma, LRG1 has a concentration of 21-50 ug/ml. It is an acute phase protein with levels elevated in patients with bacterial infections; interestingly, during the inflammatory response, LRG1 levels are not correlated with CRP levels.

P1431 | Leucine-rich Alpha 2 Glycoprotein-1 (LRG1), Human Plasma DataSheet

Biomolecule/Target :

Synonyms: Leucine-rich alpha-2-glycoprotein, LRG, LRG1

Alternates names: Leucine-rich alpha-2-glycoprotein, LRG, LRG1

Taglines: An initiator/amplifier of programmed cell death (apoptosis)

NCBI Gene ID #: 116844

NCBI Gene Symbol: LRG1

Gene Source: Human

Accession #: P02750

Recombinant: False

Source: Human Plasma

Purity by SDS-PAGE: >95%

Assay: SDS-PAGE.

Purity:

Assay #2:

Endotoxin Level:

Activity (Specifications/test method):

Biological activity:

Results:

Binding Capacity:

Unit Definition:

Molecular Weight: 50,000

Concentration:

Appearance: Sterile Filtered colorless solution

Physical form description: Liquid

Reconstitution Instructions:

Amino acid sequence:

Handling: Centrifuge the vial prior to opening.

Usage: